

ABSTRACTCOMPOUNDS

A conjugate compound comprises a cell-specific portion, such as an antibody specific to tumour cell antigens, and an enzymatically active portion which will cleave a cyanogenic compound to release cyanide. Enzymes such as β -glucosidases are suitable. The cyanogenic compound, e.g. amygdalin or some other plant-derived saccharide, is administered after the conjugate. Intravesical (intra-bladder) administration is preferred (for bladder cancers) and forms a further aspect of the invention, whether the compound is cyanide-liberating (as above) or suitable for therapy or imaging in any other way.